Summary This article provides a comprehensive, exam-focused overview of blood transfusion medicine, covering fundamental concepts of blood groups and compatibil
Summary This article provides a comprehensive, exam-focused overview of blood transfusion medicine, covering fundamental concepts of blood groups and compatibility, essential pre-transfusion testing, and the various blood products available. It details both immediate and delayed transfusion reactions, outlining their causes, clinical features, and management strategies. Special blood product modifications, the principles of massive transfusion, and critical clinical scenarios are also addressed, emphasizing patient safety and effective practice. Key Points ABO and Rh are the most critical blood group systems for compatibility, with O-negative being the universal RBC donor and AB-positive the universal plasma donor. Pre-transfusion testing involves ABO/Rh typing, antibody screening, and crossmatching to ensure compatibility. Transfusion reactions range from mild allergic responses to life-threatening acute haemolytic reactions, TACO, TRALI, and TA-GvHD, each requiring specific recognition and management. Clerical error is the most common cause of acute haemolytic transfusion reactions. Leukoreduction prevents many common reactions and infections, while irradiation is crucial for preventing TA-GvHD in susceptible patients. Massive transfusion protocols aim to replace blood volume rapidly while preventing common complications like hypothermia, hypocalcaemia, and coagulopathy. Careful patient identification and adherence to protocols are paramount for transfusion safety. Detailed Notes Fundamentals of Blood Groups and Compatibility The understanding of blood group systems is fundamental to safe transfusion practice. The ABO and Rh systems are the most clinically significant. ABO Blood Group System The ABO system is characterized by the presence or absence of A and B antigens on red blood cells (RBCs) and naturally occurring antibodies in the plasma. Blood Group Antigens on RBCs Antibodies in Plasma Can Donate To Can Receive From Notes :---------- :--------------- :------------------- :------------ :--------------- :---- A A Anti-B A, AB A, O B B Anti-A B, AB B, O AB A and B None AB only All Universal Recipient (RBCs) O None Anti-A and Anti-B All O only Universal Donor (RBCs) Universal RBC donor is O negative, while the universal plasma donor is AB positive (due to the absence of anti-A or anti-B antibodies). Rh Blood Group System and Hemolytic Disease of the Newborn (HDN) The Rh system is the second most important, primarily due to the D antigen. Individuals are Rh-positive if they have the D antigen and Rh-negative if they lack it. Unlike ABO, anti-Rh antibodies are not naturally present but develop only after exposure (sensitization) to Rh-positive RBCs, typically through transfusion or pregnancy. Pathogenesis of HDN: 1. First pregnancy: An Rh-negative mother carries an Rh-positive fetus. This pregnancy is typically uneventful for the fetus as maternal antibody production is still developing. 2. Sensitization at delivery: During delivery, fetal Rh-positive RBCs can enter the maternal circulation, leading to the mother forming anti-D IgG antibodies. 3. Subsequent Rh-positive pregnancy: In a second or later pregnancy with an Rh-positive fetus, the pre-formed maternal anti-D IgG antibodies can cross the placenta and attack the fetal RBCs, causing haemolysis. 4. Consequences: This can range from mild jaundice to severe anaemia, hydrops fetalis (severe edema), and even intrauterine death. Prevention: Administering anti-D immunoglobulin (Rhogam) to Rh-negative mothers within 72 hours of delivery or any sensitizing event (e.g., miscarriage, amniocentesis) and at 28 weeks of gestation can prevent sensitization. Other Clinically Important Blood Group Systems Beyond ABO and Rh, several other blood group systems are clinically significant due to their potential to cause haemolytic transfusion reactions and HDN. Kell system (3rd most immunogenic): Strong immunogen, can cause HDN and haemolytic transfusion reactions. Duffy system (4th most immunogenic): Individuals lacking Duffy antigens (Duffy-null) are resistant to Plasmodium vivax malaria. Kidd system (5th most immunogenic): Notorious for causing delayed haemolytic transfusion reactions. MNS system (6th most immunogenic): Has variable clinical significance. Pre-Transfusion Compatibility Testing Rigorous testing is essential to ensure donor blood is compatible with the recipient, minimizing the risk of adverse reactions. Steps of Pre-Transfusion Testing 1. ABO and Rh typing: Determines the patient's blood group and Rh status. 2. Antibody screen: Patient's serum is tested against a panel of reagent RBCs (known antigens) to detect unexpected or irregular antibodies (alloantibodies) that may cause a reaction. 3. Crossmatch: The patient's serum is directly mixed with donor RBCs. Agglutination or haemolysis indicates incompatibility, and the blood should not be transfused. Crossmatching primarily detects irregular antibodies in the patient's serum that react against specific antigens on the donor RBCs. Direct Antiglobulin Test (DAT) vs. Indirect Antiglobulin Test (IAT) These tests, also known as Coombs tests, are critical for detecting antibodies involved in haemolytic conditions. Direct Antiglobulin Test (DAT): Detects: Antibodies already bound to the patient's own RBCs in vivo (inside the body). Uses: Diagnosing haemolytic transfusion reactions, autoimmune haemolytic anaemia, and HDN. Positive DAT: Indicates that antibodies are actively coating the patient's RBCs. Indirect Antiglobulin Test (IAT): Detects: Free antibodies present in the patient's serum in vitro (in the test tube). Uses: Pre-transfusion antibody screening to identify unexpected antibodies and in crossmatching. The crossmatch is essentially a form of IAT. Metabisulfite Test The metabisulfite test is a screening tool used to detect the presence of sickle haemoglobin (HbS). Sodium metabisulfite is added to a blood sample, creating a deoxygenating environment. If HbS is present, it becomes insoluble and polymerizes, causing RBCs to sickle, which is visible microscopically. A positive result confirms the presence of HbS but does not distinguish between sickle cell trait (HbAS) and sickle cell disease (HbSS) . Haemoglobin electrophoresis is required to differentiate between these conditions. Blood Products and Their Use A variety of blood products are available, each with specific components, storage requirements, and indications. Blood Product Contents Storage Conditions Shelf Life Indications :----------------- :---------------------------------------------------------------------------- :--------------------------------- :--------------------- :---------------------------------------------------------------------------- Packed Red Blood Cells (pRBCs) Red cells, minimal plasma 1–6°C 35–42 days Symptomatic anaemia, acute haemorrhage Fresh Frozen Plasma (FFP) All coagulation factors, fibrinogen, albumin, immunoglobulins; NO platelets −18°C 12 months Coagulopathy (e.g., liver disease, warfarin reversal), DIC, TTP Platelets Platelets in plasma 20–24°C with agitation 5 days Thrombocytopenia, platelet dysfunction, prevention of bleeding in surgery Cryoprecipitate Fibrinogen, Factor VIII, Factor XIII, von Willebrand Factor (vWF), fibronectin; NO Factor IX, VII −18°C 12 months Hypofibrinogenaemia, Factor XIII deficiency, von Willebrand Disease (vWD), haemophilia A (if recombinant FVIII not available), DIC Albumin Heat-treated, virus-safe albumin Room temperature Long (up to 3 years) Hypoalbuminaemia, burns, cirrhosis with refractory ascites, nephrotic syndrome Transfusion Reactions: Immediate Transfusion reactions can occur acutely, often during or immediately after the transfusion. Prompt recognition and management are critical. Acute Haemolytic Transfusion Reaction (AHTR) This is the most serious immediate transfusion reaction . Cause: Primarily ABO incompatibility, most commonly due to clerical error (transfusing the wrong blood type to the wrong patient).